# Detection of Acid Sphingomyelinase/Ceramide Pathway Activation in Radiotherapy Patients Using Intravoxel Incoherent Motion (IVIM) Diffusion-weighted Magnetic Resonance Imaging and Serum Biomarkers

> **NCT02465723** · NA · WITHDRAWN · sponsor: **Memorial Sloan Kettering Cancer Center**

## Conditions studied

- Metastatic Disease to Bone
- Metastatic Disease to Soft Tissue

## Interventions

- **DEVICE:** MRI with IVIM DW-MRI
- **OTHER:** Blood draw

## Key facts

- **NCT ID:** NCT02465723
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-06
- **Primary completion:** 2017-06
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of accrual
- **Last updated:** 2016-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02465723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02465723, "Detection of Acid Sphingomyelinase/Ceramide Pathway Activation in Radiotherapy Patients Using Intravoxel Incoherent Motion (IVIM) Diffusion-weighted Magnetic Resonance Imaging and Serum Biomarkers". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02465723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*